WHA President Dr Su Wang intervention at the 148th session of the WHO Executive Board Meeting

WHA President Dr Su Wang intervention at the 148th session of the WHO Executive Board Meeting

The World Hepatitis Alliance (WHA) with over 300 members in just under 100 countries, welcomes the development of a new global health sector strategy for viral hepatitis as outlined in paper EB148/37 presented at the 148th session of the WHO Executive Board. 

Viral hepatitis is one of the deadliest health crises of our time, claiming more than 1.4 million lives every year. Yet, the tools to prevent, diagnose and treat viral hepatitis are readily available. With a low-cost vaccine and treatments for hepatitis B and a cure for hepatitis C, WHO’s goal of eliminating viral hepatitis by 2030 is achievable. However, less than 50% of WHO member states have reported having viral hepatitis plans in place. Without the political will for action, lives will continue to be unnecessarily lost due to hepatitis.

A new global health sector strategy for viral hepatitis is a vital tool for holding countries accountable to their commitment to reach elimination. Realistic and achievable testing and treatment targets can help find the 290 million people living with viral hepatitis unaware and link them to the care they need. Prevention targets can stop more lives being affected by viral hepatitis through harm reduction services and the prevention of mother-to-child transmission. 

The populations most impacted by viral hepatitis are often those most underserved by health systems. Civil society and the affected community are a critical catalyst to ensure that no one is left behind. Civil society and the affected community must be central to the new global health sector strategy. They need to be an integral part of the planning, implementation, monitoring and governance of hepatitis elimination programmes and services everywhere. 

The World Hepatitis Alliance and our members stand ready to support WHO in the development of the new global health strategy and commit to tirelessly working for its achievement.  

 

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close